Se connecter

Recherches récentes

Aucune recherche récente

Options de recherche

Disponible uniquement lorsque vous êtes connecté.
framapiaf.org est l'un des nombreux serveurs Mastodon indépendants que vous pouvez utiliser pour participer au fédiverse.
Un service Mastodon fourni par l'association d’éducation populaire Framasoft.

Administré par :

Statistiques du serveur :

1,4K
comptes actifs

framapiaf.org: À proposÉtatAnnuaire des profilsPolitique de confidentialité

Mastodon: À proposTélécharger l’applicationRaccourcis clavierVoir le code sourcev4.3.7

#bnt162b2

0 message0 participant0 message aujourd’hui
Auscandoc<p>Persistence of immune responses of a self-amplifying RNA <a href="https://med-mastodon.com/tags/COVID19vaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>COVID19vaccine</span></a> (ARCT-154) versus <a href="https://med-mastodon.com/tags/BNT162b2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BNT162b2</span></a> - The Lancet Infectious Diseases <a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900060-4/fulltext" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">thelancet.com/journals/laninf/</span><span class="invisible">article/PIIS1473-3099%2824%2900060-4/fulltext</span></a> “a booster dose of the novel <a href="https://med-mastodon.com/tags/mRNAVaccine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>mRNAVaccine</span></a>, <a href="https://med-mastodon.com/tags/ARCT154" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ARCT154</span></a>, a self-amplifying mRNA (<a href="https://med-mastodon.com/tags/saRNA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>saRNA</span></a>) vaccine based on the <a href="https://med-mastodon.com/tags/SARSCoV2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SARSCoV2</span></a> D614G variant (B.1), induced superior immunogenicity than BNT162b2 (Comirnaty; Pfizer–BioNTech) in BNT162b2-primed adults 1 month after administration.”</p>
Auscandoc<p>“The effectiveness of the <a href="https://med-mastodon.com/tags/BNT162b2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BNT162b2</span></a> vaccine against the <a href="https://med-mastodon.com/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Omicron</span></a> variant declined 4 months after the first dose and then stabilized. The analysis showed a lower risk for <a href="https://med-mastodon.com/tags/cardiac" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>cardiac</span></a> complications in the vaccinated group during the Omicron variant period.”</p>
Auscandoc<p>Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents | Annals of Internal Medicine <a href="https://www.acpjournals.org/doi/10.7326/M23-1754" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">acpjournals.org/doi/10.7326/M2</span><span class="invisible">3-1754</span></a> “During the <a href="https://med-mastodon.com/tags/Delta" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Delta</span></a> period, the estimated effectiveness of the <a href="https://med-mastodon.com/tags/BNT162b2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BNT162b2</span></a> vaccine was 98.4% against documented infection among <a href="https://med-mastodon.com/tags/adolescents" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>adolescents</span></a>,…During the <a href="https://med-mastodon.com/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Omicron</span></a> period, the effectiveness against documented infection among <a href="https://med-mastodon.com/tags/children" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>children</span></a> was estimated to be 74.3%</p>
Auscandoc<p>“By mid-April, 2023, individuals previously vaccinated only with wild-type vaccines had little protection against <a href="https://med-mastodon.com/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>COVID19</span></a> including hospital admission. A <a href="https://med-mastodon.com/tags/BNT162b2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BNT162b2</span></a> BA.4/5 <a href="https://med-mastodon.com/tags/bivalent" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>bivalent</span></a> <a href="https://med-mastodon.com/tags/booster" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>booster</span></a> restored protection against a range of COVID-19 outcomes, including against <a href="https://med-mastodon.com/tags/XBB" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>XBB</span></a>-related sublineages, with the most substantial protection observed against <a href="https://med-mastodon.com/tags/HospitalAdmission" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HospitalAdmission</span></a> and <a href="https://med-mastodon.com/tags/CriticalIllness" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CriticalIllness</span></a>.” <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00306-5/fulltext" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">thelancet.com/journals/lanres/</span><span class="invisible">article/PIIS2213-2600(23)00306-5/fulltext</span></a> <a href="https://bird.makeup/users/19joho/statuses/1717339296904913233" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">bird.makeup/users/19joho/statu</span><span class="invisible">ses/1717339296904913233</span></a></p>
ExplorerFlux en direct
À propos